BioWorld MedTech

July 14, 2011

Deals roundup: Private consortium set to pay $6.3 billion for Kinetic Concepts

A group of private equity investors have officially offered to buy Kinetic Concepts (KCI; San Antonio) for $68.50 a share in a cash deal valued at $6.3 billion (including KCI's outstanding debt). (Medical Device Daily) Read More

St. Jude Medical receives FDA approval for Epiducer

International report: EarlySense monitoring system now cleared for sale in Canada

Washington roundup: Foster; 'little incentive for cost-reducing technology'

Financings roundup: InSite to take part in private placement for $22.2 million

MDD's food for med-tech thought

People in the News

HIT roundup: Sermo launches new mobile application for physicians

Court Report: Acacia subsidiary settles with Boston Sci in patent dispute

Med-Tech Notes

Patent watch: Molecular Detection receives notice for antibiotic bacteria

Product Briefs

MDD's Ortho Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

ASH 2025: Ianalumab data offer break from chronic ITP therapy

BioWorld

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...